Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients
5/22/2014 9:32:26 AM
CARMIEL, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to ELELYSO™ (taliglucerase alfa) for long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia. ELELYSO will be marketed in Australia by Pfizer Inc., the Company's commercialization partner.
Help employers find you! Check out all the jobs and post your resume.
comments powered by